Daiichi Sankyo (OTCMKTS:DSNKY) Shares Gap Down - Should You Sell?
Daiichi Sankyo Co., Ltd. shares gapped down from $22.33 to $21.6960 before opening, last trading at $21.4050. Zacks Research downgraded the stock from "hold" to "strong sell," while one analyst rated it "Strong Buy" and another "Sell." The stock is down 4.2%, with a market cap of $40.52 billion and a PE ratio of 20.18. Analysts maintain a consensus rating of "Moderate Buy."
Shares of Daiichi Sankyo Co., Ltd. - Sponsored ADR (OTCMKTS:DSNKY - Get Free Report) gapped down before the market opened on Wednesday . The stock had previously closed at $22.33, but opened at $21.6960. Daiichi Sankyo shares last traded at $21.4050, with a volume of 56,682 shares changing hands.
Get Daiichi Sankyo alerts:
Wall Street Analysts Forecast Growth
- Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Separately, Zacks Research lowered shares of Daiichi Sankyo from a "hold" rating to a "strong sell" rating in a research note on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Daiichi Sankyo has a consensus rating of "Moderate Buy".
Read Our Latest Report on DSNKY
Daiichi Sankyo Stock Down 4.2%
The company has a debt-to-equity ratio of 0.06, a current ratio of 2.31 and a quick ratio of 1.60. The business's 50 day moving average price is $22.36 and its 200 day moving average price is $23.72. The firm has a market cap of $40.52 billion and a PE ratio of 20.18.
Daiichi Sankyo Company Profile
(Get Free Report)Daiichi Sankyo Co, Ltd. is a global, research-driven pharmaceutical company headquartered in Tokyo, Japan. The company was formed through the merger of Daiichi Pharmaceutical and Sankyo in 2005 and focuses on the discovery, development, manufacturing and commercialization of prescription medicines. Its therapeutic priorities include oncology and cardiovascular disease, and it pursues a mix of small molecules, biologics and antibody‑drug conjugates in its development programs.
Daiichi Sankyo is known for building a development portfolio through both internal research and collaborative partnerships.
Further Reading
- Five stocks we like better than Daiichi Sankyo
- Punch these codes into your ordinary brokerage account
- Do not delete, read immediately
- More than 2 million ounces defined - and still early in their story
- If You Keep Cash In A U.S. Bank Account… Read This NOW
- What Expenses Can Be Deducted From Capital Gains Tax?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Daiichi Sankyo Right Now?
Before you consider Daiichi Sankyo, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Daiichi Sankyo wasn't on the list.
While Daiichi Sankyo currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
